Singapore markets closed

Viatris Inc. (VTRS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
11.63-0.05 (-0.43%)
At close: 04:00PM EDT
11.40 -0.23 (-1.98%)
Pre-market: 08:00AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close11.68
Bid11.40 x 4000
Ask11.88 x 45100
Day's range11.51 - 11.93
52-week range9.66 - 15.92
Avg. volume15,578,919
Market cap14.099B
Beta (5Y monthly)1.30
PE ratio (TTM)83.67
EPS (TTM)0.14
Earnings date08 Aug 2022 - 12 Aug 2022
Forward dividend & yield0.48 (4.11%)
Ex-dividend date23 May 2022
1y target est16.78
  • CNW Group

    Viatris and Biocon Biologics Launch Abevmy® (Bevacizumab), Their Third Oncology Biosimilar, in Canada

    Viatris Inc. and Biocon Biologics Ltd., a subsidiary of Biocon Ltd., announced today that Abevmy® (bevacizumab) is now available in Canada. Abevmy, co-developed by Viatris and Biocon Biologics, is a biosimilar to Roche's Avastin® (bevacizumab) and has been approved by Health Canada across four oncology indications.

  • Motley Fool

    2 Stocks That Are Ridiculously Cheap Right Now

    Investors can look at the current market decline in one of two ways. Investors with long-term mindsets can find plenty of attractive opportunities in today's market. Viatris (NASDAQ: VTRS) appears to be a textbook value stock.

  • Motley Fool

    3 Dirt-Cheap Stocks You Can Buy Right Now

    Here's why they chose BioNTech (NASDAQ: BNTX), Pfizer (NYSE: PFE), and Viatris (NASDAQ: VTRS). David Jagielski (BioNTech): Often investors discount a stock that may seem like it is punching above its weight class, on the assumption that it may struggle down the road. BioNTech's forward price-to-earnings multiple of around 3.8 certainly suggests that investors are perhaps not taking the growth stock seriously.